Coronavirus channel feed

When will it end? Gold­man econ­o­mist gives late-stage vac­cines a good shot at tar­get­ing 'large shares' of the US by mid-2021 — but the down­side is daunt­ing

5 years ago
R&D

Sev­en plucky di­ag­nos­tics com­pa­nies win a $249M round of con­tracts af­ter sur­viv­ing NI­H's Covid-19 'Shark Tank' com­pe­ti­tion

5 years ago
Pharma

Covid-19 roundup: Eli Lil­ly retro­fits RVs for first-of-its-kind an­ti­body tri­al with NIH; Am­gen, Ab­b­Vie, Take­da team on a drug

5 years ago

Sanofi and GSK say they're near a vac­cine deal with EU hours af­ter fi­nal­iz­ing Warp Speed con­tract

5 years ago
Deals

Trump’s ‘rad­i­cal’, ‘hor­ri­ble’ ex­ec­u­tive or­ders on drug pric­ing earn a C-suite back­lash this week — with one threat to do more over­seas

5 years ago
People
Bioregnum

Brigham and Wom­en's pres­i­dent Eliz­a­beth Nabel fol­lows Mon­cef Slaoui off Mod­er­na's board

5 years ago
People

Covid-19 roundup: Roger Perl­mut­ter hus­tles up hu­man vac­cine tri­als as Mer­ck looks to catch up on Covid-19; Chi­na hacked Mod­er­na, per of­fi­cial

5 years ago

Sanofi and GSK grab largest Warp Speed deal yet, se­cur­ing $2.1B for a vac­cine that might come next year

5 years ago

Covid-19 roundup: J&J gives deep­est look yet at vac­cine; As­traZeneca shies away from dis­cussing vac­cine com­mer­cial op­por­tu­ni­ty

5 years ago

Mod­er­na, Pfiz­er be­gin to give glimpse of Covid-19 vac­cine pric­ing — and prof­its

5 years ago
Pharma

Covid-19 roundup: Mod­er­na re­moved signs around its man­u­fac­tur­ing plant — is it a tar­get for hack­ers?

5 years ago

Roche de­clares a PhI­II fail­ure for Covid-19 as the IL-6 re­pur­pos­ing the­o­ry bites the dust

5 years ago
R&D

Pfiz­er/BioN­Tech makes sur­prise choice in fi­nal dash to Oc­to­ber fin­ish line for Covid-19 vac­cine

5 years ago

Covid-19 roundup: Pe­ter Kolchin­sky’s RA Cap­i­tal spear­heads 'Covid Apol­lo,' a VC search for the best test; Up­start grabs €23M for nanobod­ies

5 years ago

Hu­mani­gen mo­men­tum barges on as Covid-19 can­di­date is se­lect­ed for NI­AID tri­al

5 years ago
R&D

Mod­er­na be­gins first US piv­otal Covid-19 vac­cine study, lands $472M more from BAR­DA

5 years ago

Af­ter Big Phar­ma aban­doned in­fec­tious dis­eases, 5 biotech con­trar­i­ans de­cid­ed to go all in. Then Covid-19 changed every­thing

5 years ago
People
In Focus

Covid-19 roundup: As­traZeneca builds $261M deal with US CD­MO play­er for bulk Covid-19 vac­cine sup­ply; Cor­po­rate in­sid­ers reel­ing in over $1B+

5 years ago

Covid-19 roundup: Hy­drox­y­chloro­quine fails again; No­vavax lines up Warp Speed man­u­fac­tur­ing part­ner

5 years ago

Covid-19 roundup: UK adds $125M to build a new vac­cine man­u­fac­tur­ing cen­ter; Pfiz­er’s $2 bil­lion con­tract sets bench­mark vac­cine price — for bet­ter or worse

5 years ago

Covid-19 roundup: Pfiz­er/BioN­Tech’s Warp Speed deal means big mon­ey for two bil­lion­aire twins; No­vavax lays out a rich smor­gas­bord of stock op­tions for ... Phase II?

5 years ago

‘So is there a plan?’ Law­mak­ers grill Warp Speed de­vel­op­ers, Pfiz­er and Mer­ck on whether they can ac­tu­al­ly de­liv­er a vac­cine this fast to every­one

5 years ago

Jus­tice De­part­ment ac­cus­es Chi­nese hack­ers of tar­get­ing US biotechs in a cy­bertheft cam­paign aimed at steal­ing Covid-19 R&D se­crets

5 years ago
China

Covid-19 roundup: Top an­a­lyst pokes hole in As­traZeneca/Ox­ford da­ta while sci­en­tists tam­per hope for fast roll­out

5 years ago
First page Previous page 46474849505152 Next page Last page
A service from the Financial Times